What was the major update for PYC Therapeutics (ASX:PYC) regarding its ADOA program?

PYC Therapeutics announced that its drug candidate, PYC-001, has been cleared by the Safety Review Committee to move into multiple-dose testing. This follows a successful 4-week safety review of patients who received a 60-microgram single dose.

What is the significance of the 60-microgram dose milestone for PYC-001?

The 60-microgram dose is the highest level tested in the single ascending dose (SAD) study to show acceptable safety and tolerability. By clearing this threshold, the company can now move this specific dosage into the Multiple Ascending Dose phase.

How does the transition to a Multiple Ascending Dose (MAD) study change the investment thesis for ASX:PYC?

The move to a MAD study shifts the narrative from "can humans tolerate one dose?" to "is the drug safe and effective over time?" For investors, this represents a significant de-risking of the clinical pipeline.

What are the primary risks for PYC Therapeutics (ASX:PYC) investors after this news?

Despite the safety clearance, the drug is still in early Phase 1/2 trials, meaning there is a high risk of failure before reaching the market. Clinical trials often face "efficacy risk," where a drug is safe but fails to actually improve vision in patients.

What market opportunity does PYC-001 target in the ophthalmology sector?

PYC-001 targets Autosomal Dominant Optic Atrophy (ADOA), which affects approximately 1 in 35,000 people globally. Because there are currently zero approved treatment options for this blinding disease, PYC-001 is chasing a "first-mover advantage" in a clinical void.

What should investors watch for in the upcoming PYC Therapeutics (ASX:PYC) data readouts?

Investors should monitor the safety and efficacy data from the MAD study, which the company expects to present throughout 2026 and 2027. Key signals will include any adverse reactions to repeated dosing and the first signs of biological activity in the eye.

PYC Therapeutics advances blinding eye disease drug trials

Written by Heidi Cuthbert Published Apr. 15 2026Last Updated Apr. 15 2026

Perth-based PYC Therapeutics (ASX:PYC) announced that its investigational drug candidate, PYC-001, has received a green light from the Safety Review Committee to progress to multiple-dose testing.

The decision follows an evaluation of safety and tolerability data from the Phase 1 single ascending dose study, specifically involving patients treated with a 60-microgram dose.

Autosomal dominant optic atrophy is a debilitating genetic condition that leads to progressive vision loss and eventual blindness.

Affecting approximately 1 in 35,000 individuals globally, the disease currently has no approved treatment options, leaving a clinical void that PYC-001 aims to fill by addressing the underlying genetic cause.

Following the SRC’s approval, the company will now integrate the 60-microgram dose into its ongoing Phase 1/2 multiple ascending dose study.

The stage will evaluate the safety and efficacy of repeat dosing, joining existing 10 and 30-microgram cohorts already under investigation.

At the time of reporting, PYC Therapeutics’ share price was $1.25.